Get the Stockscreener App
1.41
4.44%
0.06
After Hours:
1.42
0.01
+0.71%
Allogene Therapeutics Inc stock is traded at $1.41, with a volume of 5.21M.
It is up +4.44% in the last 24 hours and down -1.40% over the past month.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
See More
Previous Close:
$1.35
Open:
$1.35
24h Volume:
5.21M
Relative Volume:
1.96
Market Cap:
$316.87M
Revenue:
$95,000
Net Income/Loss:
$-327.27M
P/E Ratio:
-0.6651
EPS:
-2.12
Net Cash Flow:
$-239.25M
1W Performance:
+7.63%
1M Performance:
-1.40%
6M Performance:
+18.49%
1Y Performance:
-34.72%
1-Day Range:
$1.345
$1.48
1-Week Range:
$1.30
$1.48
52-Week Range:
$0.8621
$3.78
Allogene Therapeutics Inc Stock (ALLO) Company Profile
Name
Allogene Therapeutics Inc
Sector
Industry
Phone
(650) 457-2700
Address
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALLO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALLO
Allogene Therapeutics Inc
|
1.41 | 303.39M | 95,000 | -327.27M | -239.25M | -2.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Downgrade | JP Morgan | Neutral → Underweight |
| May-14-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Mar-14-25 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Aug-08-24 | Resumed | Oppenheimer | Outperform |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Jan-05-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-05-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-08-23 | Initiated | Citigroup | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Jan-24-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-06-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-12-22 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-10-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-15-22 | Upgrade | Goldman | Neutral → Buy |
| Jun-03-22 | Initiated | Robert W. Baird | Neutral |
| Feb-28-22 | Reiterated | B. Riley Securities | Buy |
| Oct-20-21 | Initiated | Cowen | Outperform |
| Oct-08-21 | Downgrade | Goldman | Buy → Neutral |
| Oct-08-21 | Downgrade | Stifel | Buy → Hold |
| Sep-23-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-21-21 | Resumed | Jefferies | Buy |
| May-20-21 | Upgrade | Truist | Hold → Buy |
| May-14-21 | Initiated | B. Riley Securities | Buy |
| Jan-26-21 | Upgrade | Stifel | Hold → Buy |
| Dec-10-20 | Resumed | H.C. Wainwright | Buy |
| Nov-24-20 | Initiated | BofA Securities | Buy |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Jun-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-29-20 | Reiterated | H.C. Wainwright | Buy |
| May-19-20 | Upgrade | ROTH Capital | Neutral → Buy |
| May-15-20 | Upgrade | Guggenheim | Neutral → Buy |
| May-14-20 | Reiterated | H.C. Wainwright | Buy |
| May-14-20 | Downgrade | SunTrust | Buy → Hold |
| Apr-13-20 | Initiated | SunTrust | Buy |
| Mar-13-20 | Initiated | H.C. Wainwright | Buy |
| Mar-05-20 | Initiated | Stifel | Hold |
| Feb-24-20 | Initiated | Berenberg | Hold |
| Dec-18-19 | Initiated | JMP Securities | Mkt Outperform |
| Nov-04-19 | Initiated | Canaccord Genuity | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jun-05-19 | Initiated | ROTH Capital | Neutral |
| May-31-19 | Initiated | Guggenheim | Neutral |
| May-23-19 | Initiated | Stifel | Hold |
| Mar-29-19 | Initiated | Piper Jaffray | Overweight |
View All
Allogene Therapeutics Inc Stock (ALLO) Latest News
Analysts Offer Insights on Healthcare Companies: Establishment Labs Holdings (ESTA) and Allogene Therapeutics (ALLO) - The Globe and Mail
Is Allogene Therapeutics Inc. stock attractive for growth ETFsQuarterly Growth Report & Real-Time Volume Spike Alerts - Улправда
Why Allogene Therapeutics Inc. stock is favored by pension fundsTreasury Yields & Daily Entry Point Trade Alerts - Улправда
Why Allogene Therapeutics Inc. stock is seen as undervaluedMarket Activity Recap & Verified Stock Trade Ideas - Улправда
Will Allogene Therapeutics Inc. stock reach Wall Street targetsJuly 2025 Levels & Weekly Stock Breakout Alerts - DonanımHaber
Is Allogene Therapeutics Inc. stock a buy in volatile marketsJuly 2025 Macro Moves & AI Driven Price Predictions - Улправда
Allogene Therapeutics Earnings Notes - Trefis
Allogene Arbitration Victory Pressures Cellectis Shares Tuesday - Benzinga
Allogene stock rises after favorable arbitration ruling reaffirms therapy rights By Investing.com - Investing.com South Africa
Allogene Therapeutics (ALLO) Solidifies Global Rights to Cema-ce - GuruFocus
Arbitration ruling reaffirms Allogene’s control of cancer therapy By Investing.com - Investing.com Canada
Arbitration ruling reaffirms Allogene’s control of cancer therapy - Investing.com India
Allogene Therapeutics Reaffirms Control of Cemacabtagene Ansegedleucel Following Arbitration Ruling - Quiver Quantitative
Allogene stock rises after favorable arbitration ruling reaffirms therapy rights - Investing.com
Allogene Arbitration Victory Pressures Cellectis Shares Tuesday - sahmcapital.com
Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis - GlobeNewswire
Allogene (NASDAQ: ALLO) arbitration clears path to global cema-cel rights deal - Stock Titan
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
December 2025 Penny Stocks Worth Watching - simplywall.st
Allogene Therapeutics advances ALPHA3 trial to battle relapse fears - Traders Union
Will Allogene Therapeutics Inc. stock benefit from green energy trendsForecast Cut & Stock Market Timing Techniques - Newser
Allogene Therapeutics showcases ALPHA3 study at ASH25 - Traders Union
Allogene Therapeutics CEO unveils pipeline at Piper Sandler - Traders Union
Allogene Therapeutics Up 19%, But Some Insiders Miss Out - 富途牛牛
Allogene Therapeutics (NASDAQ:ALLO) Upgraded at Wall Street Zen - MarketBeat
Could a New Alternative to a Bespoke Treatment Change the Future of Cancer Care? - Katie Couric Media
Allogene upgraded at Citizens after Q4 update - MSN
Allogene Therapeutics redefines CAR T-cell therapy with allogeneic products - Traders Union
FDA Clears Allogene's IND for CAR T Therapy in Autoimmune Diseases - MSN
Allogene Therapeutics falls after trial delay, rating downgrade post Q1 results - MSN
Can SBC Exports Limited Deliver Through Market Peaks and TroughsResistance Zone Identification & Build Winning Portfolio - earlytimes.in
Allogene Therapeutics reports Q3 EPS (19c), consensus (23c) - MSN
Allogene Therapeutics unveils ALLO-329 to combat autoimmune diseases - Traders Union
CAR-T in NHL Treatment Market Size is estimated to grow by 2034, - openPR.com
Analyzing Allogene Therapeutics Inc. with multi timeframe chartsWeekly Stock Report & Fast Moving Trade Plans - newser.com
Detecting support and resistance levels for Allogene Therapeutics Inc.Market Movement Recap & Step-by-Step Trade Execution Guides - newser.com
[Form 4] Allogene Therapeutics, Inc. Insider Trading Activity - Stock Titan
Why Allogene Therapeutics Inc. stock remains on watchlistsPortfolio Return Summary & Risk Adjusted Buy and Sell Alerts - newser.com
Allogene Therapeutics advances ALLO-329 cell therapy to transform autoimmune care - Traders Union
ALLO (Allogene Therapeutics) Construction In Progress : $0.00 Mil (As of Sep. 2025) - GuruFocus
Patient Square Capital LP Grows Position in Allogene Therapeutics, Inc. $ALLO - MarketBeat
Will breakout in Allogene Therapeutics Inc. lead to full recovery2025 Volume Leaders & Free Verified High Yield Trade Plans - newser.com
What candlestick patterns are forming on Allogene Therapeutics Inc.Weekly Trend Recap & Reliable Price Breakout Signals - newser.com
Allogene Therapeutics at Jefferies Conference: Strategic Advances in CAR-T Therapy - Investing.com Canada
VP Beneski Files To Sell 786 Of Allogene Therapeutics Inc [ALLO] - TradingView
Allogene Therapeutics Inc Stock (ALLO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):